Influenza pandemics are global outbreaks that involve viruses to which humans have little or no immunity. H5N1 is one such flu virus strain. GlaxoSmithKline has an active research and development programme targeted at both seasonal and pandemic influenza and has recently committed over a billion pounds ($2 billion) to expand capacity for manufacturing flu vaccine and its anti-viral influenza treatment Relenza® (zanamivir for inhalation). .
BTA Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
